Nov 9 (Reuters) - IMV Inc IMV.TO :
* IMV'S T CELL THERAPY DEMONSTRATES 86% OBJECTIVE RESPONSE RATE IN COMBINATION WITH MERCK'S KEYTRUDA IN PD-L1 POSITIVE PATIENTS WITH R/R DLBCL
* IMV INC - RESULTS SUPPORT INTERACTIVE MECHANISM OF ACTION OF COMBINATION TREATMENT, AND ADVANCEMENT INTO A POTENTIALLY PIVOTAL REGISTRATION TRIAL